Rotavirus Vaccine Market Report 2026

The rotavirus vaccine market size has grown rapidly in recent years. It will grow from $10.14 billion in 2025 to $11.2 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to increasing incidence of pediatric gastroenteritis, expansion of national immunization schedules, growth of public health vaccination campaigns, availability of live attenuated vaccines, rising awareness of rotavirus prevention.

The rotavirus vaccine market size is expected to see rapid growth in the next few years. It will grow to $16.45 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing demand for universal pediatric vaccination, expansion of combination vaccine development, growing investments in vaccine manufacturing capacity, rising focus on global immunization coverage, increasing collaboration with public health agencies. Major trends in the forecast period include increasing expansion of pediatric immunization programs, rising adoption of oral vaccine formulations, growing focus on vaccine cold chain optimization, expansion of public health vaccination initiatives, enhanced surveillance of rotavirus infections.

The increasing birth rates are expected to drive the growth of the rotavirus vaccine market in the coming years. Birth rates refer to the number of live births per 1,000 people in a population over a specified period, usually expressed annually. These rates are influenced by factors such as economic stability, growth, and supportive policies like parental leave, child benefits, and childcare subsidies. The use of rotavirus vaccines helps reduce the incidence of severe rotavirus gastroenteritis in infants, thereby improving child health outcomes and lowering healthcare costs related to rotavirus infections. For example, in January 2023, the Centers for Disease Control and Prevention (CDC), a US-based national public health organization, reported a 1% increase in registered births in the United States, totaling 3,664,292 compared to the previous year. As a result, rising birth rates will contribute to the growth of the rotavirus vaccine market.

Major companies in the rotavirus vaccine market are adopting oral-dosing applicators to enhance the efficiency of vaccine delivery and improve patient compliance. Oral-dosing applicators are medical devices designed to administer liquid medications or vaccines directly into the mouth, ensuring accurate dosing and ease of use, particularly for infants and young children. For instance, in June 2025, Micron Biomedical, a US-based biotechnology company, and Emory University, a US-based private university, launched a first-in-human clinical trial of the inactivated rotavirus vaccine CC24, delivered via a dissolvable microarray patch. This patch is thermostable, reducing cold chain dependency, enables self-administration, and generates no sharps waste. This innovation promises to increase vaccine access in low-resource settings, though regulatory pathways remain untested, and scaling up may pose challenges that could delay broad adoption in the rotavirus vaccine market.

In June 2024, Murdoch Children's Research Institute, an Australia-based child health research institute, partnered with Incepta Pharmaceuticals Limited to improve access to rotavirus vaccines. The collaboration aims to advance the protection of children against rotavirus by developing and distributing effective vaccines. This partnership is dedicated to expanding access to vital rotavirus vaccines, particularly in regions with high infection rates and limited healthcare resources. Incepta Pharmaceuticals Limited is a Bangladesh-based pharmaceutical company focused on developing rotavirus vaccines.

Major companies operating in the rotavirus vaccine market are Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, GlaxoSmithKline plc, Daiichi Sankyo Company Limited, Serum Institute of India Private Limited, Sinovac Biotech Ltd., SK Chemicals Co Ltd, Bharat Biotech International Limited, Walvax Biotechnology Co. Ltd., Indian Immunologicals Limited, PT Bio Farma, KFF Inc., Panacea Biotec Limited, Sanyou Biopharmaceuticals Co. Ltd., Inovio Pharmaceuticals Inc., Hilleman Laboratories Private Limited, China National Biotec Group Corporation, Vabiotech, Lanzhou Institute of Biological Products Co. Ltd., Nuvonis Pharmaceuticals Inc., Chengdu Institute of Biological Products Co. Ltd.

North America was the largest region in the rotavirus vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rotavirus vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rotavirus vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the rotavirus vaccine market by increasing costs of imported biological raw materials, vaccine production equipment, cold chain storage systems, and packaging components. Vaccine manufacturers and public immunization programs in North America and Europe are most affected due to reliance on cross-border supply chains, while Asia-Pacific faces export and distribution cost pressures. These tariffs are raising procurement costs and affecting large-scale vaccination planning. However, they are also supporting local vaccine manufacturing, regional cold chain infrastructure development, and increased self-reliance in vaccine production capabilities.

The rotavirus vaccine market research report is one of a series of new reports that provides rotavirus vaccine market statistics, including rotavirus vaccine industry global market size, regional shares, competitors with a rotavirus vaccine market share, detailed rotavirus vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the rotavirus vaccine industry. This rotavirus vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rotavirus vaccine is designed to protect against rotavirus infections, which are a leading cause of severe diarrhea and gastroenteritis in infants and young children. Administered orally, this vaccine contains live attenuated or inactivated strains of the rotavirus to trigger an immune response and provide immunity against the virus.

The primary types of rotavirus vaccines include Rotarix, RotaTeq, Rotavac, Rotavin-M1, Lanzhou Lamb, and others. Rotarix is a live attenuated oral rotavirus vaccine that protects infants from rotavirus gastroenteritis, which can lead to severe diarrhea and dehydration. The applications are categorized into adult and pediatric, with end users including hospitals, clinics, and academic research institutions.

The rotavirus vaccine market consists of sales of combination vaccines, vaccine delivery systems, vaccine doses, and packs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.